Comparing the Outcomes of MR-based Versus CT-based Tumor Delineation in Locally Advanced Non-small Cell Lung Cancer Treated with Hypo-fractionated Radiotherapy and Concurrent Chemotherapy

Overview

Journal Transl Lung Cancer Res

Date 2024 Dec 13

PMID 39670014

Authors

Pengxin Zhang

Shouliang Ding

Kangqiang Peng

Haoqiang He

Daquan Wang

Rui Zhou

Bin Wang

Jinyu Guo

Hongdong Liu

Xiaoyan Huang

Chuanmiao Xie

Hui Liu

Bo Qiu

Affiliations

Soon will be listed here.

Abstract

Background: Delineating gross tumor volume (GTV) using computed tomography (CT) imaging is the standard for lung cancer contouring, but discrepancies among observers compromise accuracy and reliability. Magnetic resonance imaging (MRI) provides superior soft-tissue resolution compared to CT, thus, we design this retrospective study to compare the treatment outcomes of magnetic resonance-based (MR-based) and CT-based tumor delineation in locally advanced non-small cell lung cancer (LA-NSCLC) patients treated with hypo-fractionated concurrent chemoradiotherapy (hypo-CCRT).

Methods: A total of 293 LA-NSCLC patients treated with hypo-CCRT from three trials between October 2015 and October 2020 were screened. Ninety patients with each MR-based delineation and CT-based delineation of the primary tumor were selected for analysis. In the MR-based delineation group, T1-enhanced MR images was rigidly registered with 10 respiratory phases of planning CT images, respectively. The primary tumors were contoured on each respiratory phase based on co-registered MRI. The locoregional progression-free survival (LPFS), progression-free survival (PFS), overall survival (OS) and toxicities in both groups were analyzed.

Results: The 2-year LPFS rate was 69.2% [95% confidence interval (CI): 59.6-80.2%] in the MR-based delineation group and 61.0% (95% CI: 50.9-73.0%) in the CT-based delineation group (P=0.37). There was no significant difference in median PFS (P=0.45) or OS (P=0.69) between the two groups. The MR-based delineation group had smaller planning target volume (186.1 315.3 cm, P<0.001), lower incidences of ≥G2 pneumonitis (10% 24.4%, P=0.001) and ≥G3 esophagitis (2.2% 15.6%, P<0.001). In evaluating the patterns of recurrence, in-field recurrences were the dominant type in both groups (21 out of 27 patients in MR-based delineation group, 24 out of 32 patients in CT-based delineation group).

Conclusions: MR-based delineation in hypo-CCRT was feasible and achieved similar treatment efficacy to CT-based delineation. The use of MR imaging to reduce the target volume resulted in promising local control and lower incidence of radiation-induced toxicities.

References

Jouglar E, Isnardi V, Goulon D, Segura-Ferlay C, Ayadi M, Dupuy C . Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: Results from the Gating 2006 trial. Radiother Oncol. 2017; 126(2):291-299. DOI: 10.1016/j.radonc.2017.11.002. View

Taugner J, Kasmann L, Eze C, Tufman A, Reinmuth N, Duell T . Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting. Cancers (Basel). 2021; 13(7). PMC: 8037429. DOI: 10.3390/cancers13071613. View

Liu F, Qiu B, Xi Y, Luo Y, Luo Q, Wu Y . Efficacy of Thymosin α1 in Management of Radiation Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043). Int J Radiat Oncol Biol Phys. 2022; 114(3):433-443. DOI: 10.1016/j.ijrobp.2022.07.009. View

Shen G, Hu S, Deng H, Kuang A . Performance of DWI in the Nodal Characterization and Assessment of Lung Cancer: A Meta-Analysis. AJR Am J Roentgenol. 2015; 206(2):283-90. DOI: 10.2214/AJR.15.15032. View

Ohno Y . New applications of magnetic resonance imaging for thoracic oncology. Semin Respir Crit Care Med. 2014; 35(1):27-40. DOI: 10.1055/s-0033-1363449. View

Abravan A, Faivre-Finn C, Kennedy J, McWilliam A, Van Herk M . Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer. J Thorac Oncol. 2020; 15(10):1624-1635. DOI: 10.1016/j.jtho.2020.06.008. View

Karki K, Saraiya S, Hugo G, Mukhopadhyay N, Jan N, Schuster J . Variabilities of Magnetic Resonance Imaging-, Computed Tomography-, and Positron Emission Tomography-Computed Tomography-Based Tumor and Lymph Node Delineations for Lung Cancer Radiation Therapy Planning. Int J Radiat Oncol Biol Phys. 2017; 99(1):80-89. PMC: 5607632. DOI: 10.1016/j.ijrobp.2017.05.002. View

Ciliberto M, Kishida Y, Seki S, Yoshikawa T, Ohno Y . Update of MR Imaging for Evaluation of Lung Cancer. Radiol Clin North Am. 2018; 56(3):437-469. DOI: 10.1016/j.rcl.2018.01.005. View

Kumar S, Holloway L, Boxer M, Yap M, Chlap P, Moses D . Variability of gross tumour volume delineation: MRI and CT based tumour and lymph node delineation for lung radiotherapy. Radiother Oncol. 2021; 167:292-299. DOI: 10.1016/j.radonc.2021.11.036. View

10.

Qi L, Zhang X, Tang L, Li J, Sun Y, Zhu G . Using diffusion-weighted MR imaging for tumor detection in the collapsed lung: a preliminary study. Eur Radiol. 2008; 19(2):333-41. DOI: 10.1007/s00330-008-1134-3. View

11.

Fleckenstein J, Jelden M, Kremp S, Jagoda P, Stroeder J, Khreish F . The Impact of Diffusion-Weighted MRI on the Definition of Gross Tumor Volume in Radiotherapy of Non-Small-Cell Lung Cancer. PLoS One. 2016; 11(9):e0162816. PMC: 5017760. DOI: 10.1371/journal.pone.0162816. View

12.

Ohno Y, Koyama H, Yoshikawa T, Kishida Y, Seki S, Takenaka D . Standard-, Reduced-, and No-Dose Thin-Section Radiologic Examinations: Comparison of Capability for Nodule Detection and Nodule Type Assessment in Patients Suspected of Having Pulmonary Nodules. Radiology. 2017; 284(2):562-573. DOI: 10.1148/radiol.2017161037. View

13.

Kong C, Zhu X, Shi M, Wang L, Chen C, Tao H . Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2020; 107(4):710-719. DOI: 10.1016/j.ijrobp.2020.03.038. View

14.

Njeh C . Tumor delineation: The weakest link in the search for accuracy in radiotherapy. J Med Phys. 2009; 33(4):136-40. PMC: 2772050. DOI: 10.4103/0971-6203.44472. View

15.

Chen N, Li Q, Wang S, Xiong M, Luo Y, Wang B . Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017). Lung Cancer. 2021; 156:82-90. DOI: 10.1016/j.lungcan.2021.04.020. View

16.

Fox J, Ford E, Redmond K, Zhou J, Wong J, Song D . Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008; 74(2):341-8. DOI: 10.1016/j.ijrobp.2008.07.063. View

17.

Owrangi A, Greer P, Glide-Hurst C . MRI-only treatment planning: benefits and challenges. Phys Med Biol. 2018; 63(5):05TR01. PMC: 5886006. DOI: 10.1088/1361-6560/aaaca4. View

18.

Zhou R, Qiu B, Xiong M, Liu Y, Peng K, Luo Y . Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049). Int J Radiat Oncol Biol Phys. 2023; 117(2):387-399. DOI: 10.1016/j.ijrobp.2023.04.021. View

19.

Dixon W . Simple proton spectroscopic imaging. Radiology. 1984; 153(1):189-94. DOI: 10.1148/radiology.153.1.6089263. View

20.

Abe T, Saito S, Iino M, Aoshika T, Ryuno Y, Ohta T . Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone. Thorac Cancer. 2020; 12(2):245-250. PMC: 7812072. DOI: 10.1111/1759-7714.13764. View